AQST
Aquestive Therapeutics, Inc.
$3.99
+2.05%
$490.5M
No data for this timeframe.
Vol
Market Cap$490.5M
Cap SizeSmall Cap
Inst. Holders8 funds
Inst. Value$72.1M
Inst. Activity4 buys / 0 sells
Insider Activity0B / 8S
Insider Net $-$1.7M
Reddit Sentiment50° Neutral
SEC Reports3
Press Releases1
Recent Activity
Jun 8, 2026
Insider
Korczynski Sherry sold 2,714 shares
Chief Commercial Officer @ $0.00 ($0.00)
Jun 8, 2026
short_volume
Short Volume: AQST — 64.9% short (0.6M / 0.9M)
Short: 563,274 | Exempt: 340 | TRF Vol: 868,100 | Short Ratio: 64.9% | Off-exchange volume (dark poo
May 18, 2026
Insider
Zalewski Thomas A. sold 100,000 shares
Chief Legal Officer @ $0.00 ($0.00)
May 18, 2026
Insider
Zalewski Thomas A. sold 75,000 shares
Chief Legal Officer @ $0.00 ($0.00)
May 13, 2026
SEC
Aquestive reported Q1 2026 revenue of $14.4M (up 66% YoY) and a net loss of $0.07/share, well above the $-0.14 consensus
8-K — Impact 7/10
Mar 11, 2026
SEC
Multiple C-suite executives at Aquestive Therapeutics (AQST) sold shares in the open market, with the CFO, COO, and Chie
CLUSTER — Impact 6/10
Mar 4, 2026
SEC
Aquestive Therapeutics reported Q4 and full-year 2025 financial results, received a Complete Response Letter (CRL) from
8-K — Impact 7/10
Inst.
WELLS FARGO & COMPANY/MN — DOUBLED
1,188,531 shares ($7.7M)
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$8.89 (Nov 2025)
Current $3.99
Low $6.00
Median $9.00
High $11.00
9 analysts
$6.00
$11.00
Analyst Ratings
4Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 7, 2025 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Oct 9, 2025 | JMP Securities | MAINTAIN | Market Outperform → Market Outperform |
| Sep 8, 2025 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Jun 17, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 15, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▼ -4.3% | $-0.14 — $-0.10 | -2% YoY | 2 |
| Next Q | $-0.12 ▼ -9.1% | $-0.14 — $-0.10 | -5% YoY | 2 |
| Current FY | $-0.42 ▲ +8.7% | $-0.48 — $-0.36 | 29% YoY | 2 |
| Next FY | $-0.45 ▲ +22.4% | $-0.45 — $-0.45 | -7% YoY | 1 |
Latest Reports
BULLISH
8-K
7/10
Aquestive reported Q1 2026 revenue of $14.4M (up 66% YoY) and a net loss of $0.07/share, well above the $-0.14 consensus
May 13, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at Aquestive Therapeutics (AQST) sold shares in the open market, with the CFO, COO, and Chie
Mar 11, 2026
MIXED
Press
6/10
Aquestive Therapeutics reported mixed Q4 and full-year 2025 results, with 10% quarterly revenue growth to $13.0M but a 3
Mar 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $38.1M | ADD |
| MORGAN STANLEY | $11.4M | DOUBLED |
| BANK OF AMERICA CORP | $7.8M | — |
| WELLS FARGO & COMPANY/MN | $7.7M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $2.7M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Korczynski Sherry | F | $0.00 |
| May 18, 2026 | Zalewski Thomas | A | $0.00 |
| May 18, 2026 | Zalewski Thomas | A | $0.00 |
| May 15, 2026 | Cioffi Melina | F | $7.0K |
| May 15, 2026 | Barber Daniel | SELL | $35.4K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $72.1M total value (11,159,156 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 5,892,334 | $38.1M | 52.8% | ADD +30.8% |
| 2 | MORGAN STANLEY | 1,758,750 | $11.4M | 15.8% | DOUBLED +107.3% |
| 3 | BANK OF AMERICA CORP /DE/ | 1,207,591 | $7.8M | 10.8% | — |
| 4 | WELLS FARGO & COMPANY/MN | 1,188,531 | $7.7M | 10.7% | DOUBLED +804.6% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 414,400 | $2.7M | 3.7% | DOUBLED +376.3% |
| 6 | TWO SIGMA INVESTMENTS, LP | 381,120 | $2.5M | 3.4% | NEW |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 301,521 | $1.9M | 2.7% | NEW |
| 8 | FMR LLC | 14,909 | $96.3K | 0.1% | DOUBLED +207.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | DOUBLED | 131,386 | 1,188,531 | +804.6% | $7.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 87,000 | 414,400 | +376.3% | $2.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 381,120 | — | $2.5M | 2025-Q4 |
| FMR LLC | DOUBLED | 4,854 | 14,909 | +207.1% | $96.3K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 4,328,505 | 5,662,132 | +30.8% | $31.7M | 2025-Q3 |
| UBS Group AG | ADD | 361,264 | 499,036 | +38.1% | $2.8M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 103,431 | 131,386 | +27.0% | $734.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 87,000 | — | $486.3K | 2025-Q3 |
| FMR LLC | DOUBLED | 2,330 | 4,854 | +108.3% | $27.1K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 239,914 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 372,063 | 239,914 | -35.5% | $794.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 55,452 | 103,431 | +86.5% | $342.4K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 736,889 | 1,527,289 | +107.3% | $4.4M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 464,978 | 596,550 | +28.3% | $1.7M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 175,952 | 372,063 | +111.5% | $1.1M | 2025-Q1 |
| UBS Group AG | TRIM | 420,563 | 314,329 | -25.3% | $911.6K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 75,645 | 2,347 | -96.9% | $6.8K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 95,400 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 1,007,033 | 464,978 | -53.8% | $1.7M | 2024-Q4 |
| UBS Group AG | DOUBLED | 90,689 | 420,563 | +363.7% | $1.5M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 28,600 | 95,400 | +233.6% | $339.6K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 33,392 | 51,522 | +54.3% | $183.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 203,540 | — | $1.0M | 2024-Q3 |
10 unique insiders with 8 transactions. Net insider value: -$1.7M ($0.00 bought, $1.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Korczynski Sherry | Chief Commercial Officer | F | 2,714 | $0.00 | $0.00 |
| May 18, 2026 | Zalewski Thomas A. | Chief Legal Officer | A | 100,000 | $0.00 | $0.00 |
| May 18, 2026 | Zalewski Thomas A. | Chief Legal Officer | A | 75,000 | $0.00 | $0.00 |
| May 15, 2026 | Cioffi Melina | SVP, Regulatory Affairs | F | 1,667 | $4.17 | $7.0K |
| May 15, 2026 | Barber Daniel | President and CEO | SELL | 8,257 | $4.29 | $35.4K |
| May 7, 2026 | BRAENDER LORI J | Corporate Secretary | F | 135,690 | $4.23 | $574.0K |
| May 5, 2026 | BRAENDER LORI J | Corporate Secretary | F | 76,147 | $4.18 | $318.3K |
| May 5, 2026 | Jung Cassie | Chief Operating Officer | F | 72,734 | $4.18 | $304.0K |
| May 5, 2026 | TOTH A ERNEST JR | Chief Financial Officer | F | 92,652 | $4.18 | $387.3K |
| May 5, 2026 | Boyd Peter E. | Chief People Officer | F | 56,778 | $4.18 | $237.3K |
| May 5, 2026 | Barber Daniel | President and CEO | F | 335,922 | $4.18 | $1.4M |
| Mar 10, 2026 | Jung Cassie | Chief Operating Officer | SELL | 45,791 | $4.17 | $191.1K |
| Mar 10, 2026 | TOTH A ERNEST JR | Chief Financial Officer | SELL | 58,254 | $4.17 | $243.1K |
| Mar 10, 2026 | BRAENDER LORI J | Chief Legal Officer | SELL | 40,102 | $4.17 | $167.3K |
| Mar 10, 2026 | Barber Daniel | President and CEO | SELL | 180,677 | $4.17 | $754.0K |
| Mar 10, 2026 | Boyd Peter E. | Chief People Officer | SELL | 29,814 | $4.17 | $124.4K |
| Mar 10, 2026 | Cioffi Melina | SVP, Regulatory Affairs | SELL | 25,311 | $4.17 | $105.6K |
| Mar 10, 2026 | Korczynski Sherry | Chief Commercial Officer | SELL | 15,741 | $4.17 | $65.7K |
| Mar 9, 2026 | Greenhawt Matthew J. | Chief Medical Officer | A | 75,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Davis Matthew W. | Chief Development Officer | A | 50,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Jung Cassie | Chief Operating Officer | A | 80,000 | $0.00 | $0.00 |
| Mar 9, 2026 | TOTH A ERNEST JR | Chief Financial Officer | A | 95,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Davis Matthew W. | Chief Development Officer | A | 50,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Jung Cassie | Chief Operating Officer | A | 42,500 | $0.00 | $0.00 |
| Mar 9, 2026 | Korczynski Sherry | Chief Commercial Officer | A | 42,500 | $4.29 | $182.3K |
| Mar 9, 2026 | TOTH A ERNEST JR | Chief Financial Officer | A | 70,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Cioffi Melina | SVP, Regulatory Affairs | A | 75,000 | $4.29 | $321.8K |
| Mar 9, 2026 | BRAENDER LORI J | Chief Legal Officer | A | 80,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Barber Daniel | President and CEO | A | 523,000 | $4.29 | $2.2M |
| Mar 9, 2026 | Boyd Peter E. | Chief People Officer | A | 80,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Boyd Peter E. | Chief People Officer | A | 42,500 | $4.29 | $182.3K |
| Mar 9, 2026 | Barber Daniel | President and CEO | A | 262,000 | $0.00 | $0.00 |
| Mar 9, 2026 | BRAENDER LORI J | Chief Legal Officer | A | 50,000 | $4.29 | $214.5K |
| Mar 9, 2026 | Cioffi Melina | SVP, Regulatory Affairs | A | 100,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Korczynski Sherry | Chief Commercial Officer | A | 75,000 | $0.00 | $0.00 |
| Mar 9, 2026 | Greenhawt Matthew J. | Chief Medical Officer | A | 50,000 | $4.29 | $214.5K |
| Mar 7, 2025 | TOTH A ERNEST JR | SVP, Chief Financial Officer | A | 82,500 | $0.00 | $0.00 |
| Mar 7, 2025 | BRAENDER LORI J | Corporate Secretary | A | 82,500 | $0.00 | $0.00 |
| Mar 7, 2025 | Jung Cassie | Chief Operating Officer | A | 60,000 | $0.00 | $0.00 |
| Mar 7, 2025 | Boyd Peter E. | Chief People Officer | A | 60,000 | $0.00 | $0.00 |
| Mar 7, 2025 | Korczynski Sherry | Chief Commercial Officer | A | 67,500 | $0.00 | $0.00 |
| Mar 7, 2025 | Barber Daniel | President and CEO | A | 293,100 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 0 neutral. Avg impact: 6.7/10.
BULLISH
8-K
7/10
Aquestive reported Q1 2026 revenue of $14.4M (up 66% YoY) and a net loss of $0.07/share, well above
May 13, 2026
BEARISH
CLUSTER
6/10
Multiple C-suite executives at Aquestive Therapeutics (AQST) sold shares in the open market, with th
Mar 11, 2026
MIXED
8-K
7/10
Aquestive Therapeutics reported Q4 and full-year 2025 financial results, received a Complete Respons
Mar 4, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 93% buy across 15 analysts — 4 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$8.89 mean target (Nov 2025)
$6.00 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $3.99 |
| Target Low | $6.00 |
| Target Mean | $8.89 |
| Target Median | $9.00 |
| Target High | $11.00 |
| # Analysts | 9 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.14 | $-0.10 | -2.2% | -4.3% | 0↑ 1↓ | $0.0B | 15.6% | 2 |
| Next Q 2026-09-30 |
$-0.12 | $-0.14 | $-0.10 | -4.7% | -9.1% | 0↑ 1↓ | $0.0B | -5.6% | 2 |
| Current FY 2026-12-31 |
$-0.42 | $-0.48 | $-0.36 | 28.7% | +8.7% | 1↑ 0↓ | $0.1B | 13.4% | 2 |
| Next FY 2027-12-31 |
$-0.45 | $-0.45 | $-0.45 | -7.1% | +22.4% | 0↑ 1↓ | $0.1B | 42.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $-0.115 | -0.005 |
| 30d ago | $-0.115 | -0.005 |
| 60d ago | $-0.115 | -0.005 |
| 90d ago | $-0.130 | +0.010 |
10 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 7, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Oct 9, 2025 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Sep 8, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jun 17, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 7, 2025 | Lake Street | MAINTAIN | Buy | Buy |
| Dec 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 17, 2024 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Nov 11, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 25, 2024 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Oct 25, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 8, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Sep 30, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Sep 30, 2024 | Leerink Partners | REITERATE | Outperform | Outperform |
| Sep 30, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 12, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jul 26, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 26, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jun 5, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 10, 2024 | Leerink Partners | INITIATE | — | Outperform |
| May 9, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 30, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 11, 2024 | Piper Sandler | INITIATE | — | Overweight |
| Apr 5, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 28, 2024 | Raymond James | INITIATE | — | Outperform |
| Mar 18, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 15, 2024 | JMP Securities | MAINTAIN | Outperform | Outperform |
| Mar 11, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 7, 2024 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 7, 2024 | Lake Street | MAINTAIN | Buy | Buy |
| Nov 8, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Oct 10, 2023 | Wedbush | REITERATE | Outperform | Outperform |
| Oct 10, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 22, 2023 | Wedbush | REITERATE | Outperform | Outperform |
| Sep 22, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 21, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jul 31, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 30, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jun 21, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 9, 2023 | Wedbush | UPGRADE | Neutral | Outperform |
| Nov 4, 2022 | Alliance Global Partners | MAINTAIN | — | Buy |
| Sep 7, 2022 | Oppenheimer | INITIATE | — | Outperform |
| Sep 6, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Aug 30, 2022 | Alliance Global Partners | INITIATE | — | Buy |
| Aug 15, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
1 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 5, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 5, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Feb 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 8, 2026
short_volume
Short Volume: AQST — 64.9% short (0.6M / 0.9M)
Short: 563,274 | Exempt: 340 | TRF Vol: 868,100 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: AQST — 72.3% short (0.8M / 1.1M)
Short: 769,660 | Exempt: 3,688 | TRF Vol: 1,063,930 | Short Ratio: 72.3% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: AQST — 60.1% short (0.5M / 0.8M)
Short: 464,365 | Exempt: 2,895 | TRF Vol: 772,727 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: AQST — 64.9% short (0.5M / 0.8M)
Short: 510,716 | Exempt: 112 | TRF Vol: 786,465 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: AQST — 60.6% short (0.4M / 0.6M)
Short: 359,228 | Exempt: 2,243 | TRF Vol: 592,878 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: AQST — 57.2% short (0.3M / 0.6M)
Short: 320,860 | Exempt: 1 | TRF Vol: 561,373 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
AQST Q1 2026 Earnings After Market Close — 2026-05-13
May 12, 2026
other
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
<p align="justify">WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a phar
May 11, 2026
earnings_calendar
AQST Q1 2026 Earnings After Market Close — 2026-05-11
May 5, 2026
earnings_calendar
AQST Q1 2026 Earnings After Market Close — 2026-05-05
Apr 22, 2026
short_volume
Short Volume: AQST — 65.8% short (0.7M / 1.1M)
Short: 721,926 | Exempt: 865 | TRF Vol: 1,097,240 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_volume
Short Volume: AQST — 58.0% short (0.4M / 0.7M)
Short: 384,747 | Exempt: 1,016 | TRF Vol: 663,100 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: AQST — 60.5% short (0.3M / 0.6M)
Short: 339,585 | Exempt: 1,407 | TRF Vol: 561,532 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Mar 20, 2026
other
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
<p align="justify">WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a ph
Mar 9, 2026
other
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
<p align="justify">WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a ph